Tennessee Oncology | Association Partnerships

Latest from Tennessee Oncology

DS-6000a Displays Early Clinical Activity in Ovarian Cancer and RCC

August 24, 2022

In an interview with Targeted Oncology, Erika P. Hamilton, MD, discussed the early clinical activity seen with DS-6000a in patients with advanced ovarian cancer or renal cell carcinoma with disease progression following standard of care treatment.

Cilta-cel Shows Deep and Durable Responses for R/R Multiple Myeloma

June 22, 2022

Jesus G. Berdeja, MD, director of multiple myeloma research at Sarah Cannon Research Institute and hematology specialist at Tennessee Oncology, discusses the results of the CARTITUDE-1 trial for chimeric antigen receptor T-cell therapy with the newly-approved agent ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.